HS-276，25MG，SML3629-25MG，Sigma

Biochem/physiol Actions

HS-276 is an orally active, potent and selective TGF-β-activated kinase-1 (TAK-1; TAK1) inhibitor (Ki = 2.5 nM; IC50 = 8.25 nM) that significantly reduced cytokines production in THP-1 human macrophages upon LPS/IFNγ treatment (IC50 = 138 nM/TNF, 201 nM/IL-6, and 234 nM/IL-1β). HS-276 effectively attenuates arthritic-like symptoms in the CIA mouse rheumatoid arthritis (RA) model (10-30 mg/kg/d p.o. or 25 mg/kg/d i.p.).
Orally available, potent and selective TGF-β-activated kinase-1 (TAK-1; TAK1) inhibitor.